EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Nanobiotix created a subsidiary, Curadigm, to step up the use of nanoparticles to improve drug safety and bioavailability. Statement 

> Freeline posted preclinical data on its Fabry disease gene therapy. A single dose of the therapy sent GLA levels up to 1,061-fold higher than those of wild-type mice. Release 

> Transgene completed enrollment in a phase 2 trial that is testing TG4010 in combination with Opdivo. The milestone sets Transgene up to report primary endpoint data later this year. Statement  

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Mereo BioPharma posted six-month data from the open-label arm of a phase 2b trial in brittle bone disease. The data suggest setrusumab may improve bone density when Mereo reports data from the full study later this year. Statement 

> Orchard Therapeutics secured the worldwide license to an autologous hematopoietic stem cell gene therapy program for the treatment of Mucopolysaccharidosis Type I. Release  

> F-star completed the dose escalation phase of its FS118 study without seeing dose-limiting toxicities. Release 

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.